Viking Therapeutics jumps as obesity updates outshine Q3 beat
Seeking Alpha News (Thu, 24-Oct 11:26 AM ET)
VKTX Iron Condor Can Make 85% in Next 16 Days
Market Chameleon (Thu, 24-Oct 10:42 AM ET)
Promising Pipeline Developments and Strategic Initiatives Justify Buy Rating for Viking Therapeutics
TipRanks (Thu, 24-Oct 10:37 AM ET)
Stifel Nicolaus Sticks to Its Buy Rating for Viking Therapeutics (VKTX)
TipRanks (Thu, 24-Oct 8:17 AM ET)
Truist Financial Keeps Their Buy Rating on Viking Therapeutics (VKTX)
TipRanks (Thu, 24-Oct 7:40 AM ET)
TipRanks (Thu, 24-Oct 7:40 AM ET)
Positive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity Program
TipRanks (Thu, 24-Oct 6:40 AM ET)
Viking Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
TipRanks (Thu, 24-Oct 6:28 AM ET)
Viking Therapeutics GAAP EPS of -$0.22 beats by $0.03
Seeking Alpha News (Wed, 23-Oct 4:14 PM ET)
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PRNewswire (Wed, 23-Oct 4:05 PM ET)
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Viking Therapeutics trades on the NASDAQ stock market under the symbol VKTX.
As of October 24, 2024, VKTX stock price climbed to $73.22 with 15,777,591 million shares trading.
VKTX has a beta of 3.24, meaning it tends to be more sensitive to market movements. VKTX has a correlation of 0.12 to the broad based SPY ETF.
VKTX has a market cap of $8.11 billion. This is considered a Mid Cap stock.
In the last 3 years, VKTX traded as high as $99.41 and as low as $2.02.
The top ETF exchange traded funds that VKTX belongs to (by Net Assets): VTI, XBI, VB, VXF, VBK.
VKTX has outperformed the market in the last year with a price return of +605.4% while the SPY ETF gained +39.4%. VKTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +42.1% and +16.9%, respectively, while the SPY returned +4.9% and +0.4%, respectively.
VKTX support price is $58.35 and resistance is $62.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VKTX shares will trade within this expected range on the day.